
Opinion|Videos|May 6, 2024
Efficacy and Safety of Aflibercept 8 mg in PHOTON Trial in DMO
Author(s)Marion Munk, MD, PhD
Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.
Advertisement
Episodes in this series
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement

































